KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting... Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia.
- Mechanism
- Curator reviewed
KAI-1455 is a selective epsilon protein kinase C (εPKC) activator. It reduces damage during surgical procedures, such as coronary artery bypass grafting, vascular surgery and pediatric cardiac surgery N.B. begun dosing protein tyrosine phosphatase 1B (PTP1B).
- Primary indication
- Investigated for use/treatment in ischemic reperfusion injury.Curator reviewed
- Code names
- KAI-1455
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with KAI-1455, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account